GRN

Bozeman Health Becomes the First Montana Member of Guardian Research Network, Inc.®

Retrieved on: 
Tuesday, May 7, 2024

SPARTANBURG, S.C., May 7, 2024 /PRNewswire/ -- Guardian Research Network (GRN) announced today that Bozeman Health joined its national consortium dedicated to expanding access to research studies to accelerate cure discoveries and care improvements. This relationship will bolster the health system's growing clinical research enterprise, which focuses on diseases in the areas of oncology, gastroenterology, and infectious disease.

Key Points: 
  • SPARTANBURG, S.C., May 7, 2024 /PRNewswire/ -- Guardian Research Network (GRN) announced today that Bozeman Health joined its national consortium dedicated to expanding access to research studies to accelerate cure discoveries and care improvements.
  • This relationship will bolster the health system's growing clinical research enterprise, which focuses on diseases in the areas of oncology, gastroenterology, and infectious disease.
  • "Collaborating with GRN will enable us to further contribute to the development and awareness of new diagnostic methods for diseases and better understand certain illnesses through clinical research," said Kathryn Bertany, MD, Bozeman Health Chief Executive Officer.
  • "Using deep data analytics, we do just that by identifying patients Bozeman Health's research team can contact to educate them on the option to volunteer.

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Retrieved on: 
Tuesday, April 16, 2024

SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.

Key Points: 
  • SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.
  • “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families.
  • The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • “We are proud to support AviadoBio and the team at Mazowiecki Szpital Bródnowski Hospital, as well as other clinical trial sites to come in Europe and the United States.”
    More information about the ASPIRE-FTD study can be found at https://clinicaltrials.gov/study/NCT06064890.

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Retrieved on: 
Monday, April 15, 2024

AviadoBio , a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN).

Key Points: 
  • AviadoBio , a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN).
  • Clinical trial sites are currently open in Poland, Spain, and the Netherlands with additional sites expected to open in multiple countries, including the United States.
  • “AviadoBio is committed to bringing forward an innovative gene therapy treatment for FTD-GRN and this moment marks an important milestone for the FTD community and our company,” said Lisa Deschamps, CEO.
  • It has also received orphan drug designation by both the FDA and European Commission.

LJP Waste Solutions Announces Michael Malatesta as its new Chief Executive Officer

Retrieved on: 
Thursday, April 4, 2024

LJP Waste Solutions , a leading provider of zero landfill and traditional waste management services, announced the appointment of Michael Malatesta as its new Chief Executive Officer, effective April 2, 2024.

Key Points: 
  • LJP Waste Solutions , a leading provider of zero landfill and traditional waste management services, announced the appointment of Michael Malatesta as its new Chief Executive Officer, effective April 2, 2024.
  • Retiring CEO Steve Metz will remain on the LJP board and support key organic and inorganic growth initiatives.
  • I look forward to joining the LJP team and advancing our strategic initiatives,” said CEO Mike Malatesta.
  • Mr. Malatesta was introduced to LJP Waste Solutions by Tyler Frisbie , the President of executive search firm Frisbie Search Partners, Inc. DBA - GRN McKinney.

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, March 4, 2024

"In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.

Key Points: 
  • "In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.
  • We eagerly anticipate a catalyst-rich 2024, supported by our robust balance sheet, bringing us closer to improving patient outcomes across neurodegenerative diseases."
  • Additionally, Dose 1 of PBFT02 continued to be generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression.
  • Cash Position: Cash, cash equivalents and marketable securities were $114.3 million as of December 31, 2023, as compared to $189.6 million as of December 31, 2022.

Medical University of South Carolina Joins the Guardian Research Network

Retrieved on: 
Wednesday, February 21, 2024

SPARTANBURG, S.C., Feb. 21, 2024 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) announced today that the Medical University of South Carolina (MUSC), the only comprehensive academic health system in the state, joined its nationwide consortium of healthcare organizations as the first academic medical center member. This strategic collaboration will augment GRN's mission to expedite cure discovery and care improvements, as well as MUSC's mission to fuel research, education, and innovative care for improved patient outcomes.

Key Points: 
  • SPARTANBURG, S.C., Feb. 21, 2024 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) announced today that the Medical University of South Carolina (MUSC), the only comprehensive academic health system in the state, joined its nationwide consortium of healthcare organizations as the first academic medical center member.
  • This strategic collaboration will augment GRN's mission to expedite cure discovery and care improvements, as well as MUSC's mission to fuel research, education, and innovative care for improved patient outcomes.
  • "Adding a prestigious academic health system elevates the entire GRN network," comments Bruce Holstien, GRN's chief executive officer.
  • "Their innovative leadership, clinical excellence and research expertise will add another dimension to our network as we all work together to create the next generation of care."

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson's disease

Retrieved on: 
Tuesday, January 23, 2024

Fox Foundation for Parkinson's Research (MJFF) to assess sortilin inhibition in Parkinson's disease.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) to assess sortilin inhibition in Parkinson's disease.
  • The grant was awarded under the MJFF's Parkinson's Disease Therapeutics Pipeline Program (Pre-Clinical).
  • The program seeks to advance preclinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson's disease.
  • We are proud to fund the work of researchers at Vesper Bio as they investigate new ways to fulfil the unmet needs of people with Parkinson's."

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson's disease

Retrieved on: 
Tuesday, January 23, 2024

Fox Foundation for Parkinson's Research (MJFF) to assess sortilin inhibition in Parkinson's disease.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) to assess sortilin inhibition in Parkinson's disease.
  • The grant was awarded under the MJFF's Parkinson's Disease Therapeutics Pipeline Program (Pre-Clinical).
  • The program seeks to advance preclinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson's disease.
  • We are proud to fund the work of researchers at Vesper Bio as they investigate new ways to fulfil the unmet needs of people with Parkinson's."

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Retrieved on: 
Wednesday, December 20, 2023

Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.

Key Points: 
  • Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
  • "We are proud to announce initial clinical data from our upliFT-D clinical trial, which showcases the ability of PBFT02 to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment.
  • The upliFT-D clinical trial evaluates PBFT02 as a single dose delivered via intra-cisterna magna (ICM) injection.
  • These strategic priorities and clinical milestones underscore Passage Bio's dedication to advancing cutting-edge, one-time genetic medicines and protecting patients and families against loss in neurodegenerative conditions.

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023

Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025

Key Points: 
  • Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025
    PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023, and provided recent business highlights.
  • "Our team remains focused on execution, and this past quarter marked another stride toward achieving key milestones across our two lead clinical programs.
  • Initial data focused on safety and CSF progranulin levels from three Cohort 1 patients is expected in the fourth quarter of 2023.
  • Present initial safety and biomarker data from three Cohort 1 patients in upliFT-D clinical trial for FTD in Q4 2023.